1832 Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-5
| Closed | -$1.28K | – | 840 |
|
|
2023
Q3 | $1.28K | Buy |
+5
| New | +$1.34K | ﹤0.01% | 824 |
|
|
2022
Q4 | – | Sell |
-35,700
| Closed | -$9.53M | – | 897 |
|
|
2022
Q3 | $9.53M | Buy |
+35,700
| New | +$7.58M | 0.02% | 371 |
|
|
2022
Q2 | – | Sell |
-10
| Closed | -$2K | – | 865 |
|
|
2022
Q1 | $2K | Hold |
10
| – | – | ﹤0.01% | 913 |
|
|
2021
Q4 | $2K | Sell |
10
-1,082
| -99% | -$278K | ﹤0.01% | 690 |
|
|
2021
Q3 | $314K | Buy |
+1,092
| New | +$358K | ﹤0.01% | 607 |
|
|
2020
Q2 | – | Sell |
-43,700
| Closed | -$13.9M | – | 655 |
|
|
2020
Q1 | $13.9M | Buy |
+43,700
| New | +$13.3M | 0.05% | 204 |
|
|
2019
Q3 | – | Sell |
-4,500
| Closed | -$1.08M | – | 670 |
|
|
2019
Q2 | $1.08M | Buy |
4,500
+4,473
| +16,567% | +$1.03M | ﹤0.01% | 456 |
|
|
2019
Q1 | $6K | Buy |
27
+22
| +440% | +$6.93K | ﹤0.01% | 589 |
|
|
2018
Q4 | $2K | Sell |
5
-32,626
| -100% | -$10.4M | ﹤0.01% | 607 |
|
|
2018
Q3 | $11.4M | Buy |
32,631
+12,771
| +64% | +$4.4M | 0.04% | 220 |
|
|
2018
Q2 | $5.74M | Sell |
19,860
-31,874
| -62% | -$8.96M | 0.02% | 281 |
|
|
2018
Q1 | $14M | Sell |
51,734
-10,966
| -17% | -$3.4M | 0.05% | 202 |
|
|
2017
Q4 | $19.8M | Sell |
62,700
-101,186
| -62% | -$32.5M | 0.06% | 185 |
|
|
2017
Q3 | $49.7M | Buy |
163,886
+26,886
| +20% | +$7.96M | 0.17% | 113 |
|
|
2017
Q2 | $37.2M | Buy |
137,000
+18,400
| +16% | +$4.87M | 0.17% | 133 |
|
|
2017
Q1 | $32.5M | Sell |
118,600
-47,000
| -28% | -$13.3M | 0.12% | 162 |
|
|
2016
Q4 | $47M | Sell |
165,600
-10,720
| -6% | -$3.18M | 0.14% | 151 |
|
|
2016
Q3 | $55.2M | Sell |
176,320
-22,680
| -11% | -$6.72M | 0.21% | 111 |
|
|
2016
Q2 | $48.4M | Buy |
199,000
+5,980
| +3% | +$1.58M | 0.19% | 118 |
|
|
2016
Q1 | $82.6M | Sell |
193,020
-4,780
| -2% | -$1.26M | 0.2% | 118 |
|
|
2015
Q4 | $61.2M | Buy |
197,800
+25,460
| +15% | +$7.32M | 0.26% | 96 |
|
|
2015
Q3 | $50.5M | Sell |
172,340
-34,449
| -17% | -$11.4M | 0.21% | 106 |
|
|
2015
Q2 | $83.4M | Sell |
206,789
-223,132
| -52% | -$89.5M | 0.28% | 85 |
|
|
2015
Q1 | $180M | Buy |
429,921
+263,920
| +159% | +$104M | 0.68% | 41 |
|
|
2014
Q4 | $56.3M | Sell |
166,001
-295,880
| -64% | -$95.7M | 0.17% | 122 |
|
|
2014
Q3 | $152M | Buy |
461,881
+50,366
| +12% | +$16.6M | 0.5% | 53 |
|
|
2014
Q2 | $129M | Buy |
411,515
+189,815
| +86% | +$57.1M | 0.41% | 63 |
|
|
2014
Q1 | $64.4M | Buy |
+221,700
| New | +$70.4M | 0.22% | 111 |
|
Other funds holding BIIB
1832 Asset Management's BIIB Position: Q4 2023 in Review
1832 Asset Management sold out of Biogen (BIIB) in Q4 2023, closing a stake of 5 shares — an estimated $1.28K sold.
1832 Asset Management first reported a position in BIIB in Q1 2014 and held it in 28 quarters. The position peaked at $180M in Q1 2015. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.
- 1832 Asset Management reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
- 1832 Asset Management sold 5 Biogen shares in Q4 2023, an estimated $1.28K.
- 1832 Asset Management first reported a position in Biogen in Q1 2014 and held it in 28 quarters.
- 1832 Asset Management's Biogen position peaked at $180M in Q1 2015.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.
Based on 1832 Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.